140 related articles for article (PubMed ID: 9258604)
1. Resistance mechanisms and their regulation in lung cancer.
Volm M; Mattern J
Crit Rev Oncog; 1996; 7(3-4):227-44. PubMed ID: 9258604
[TBL] [Abstract][Full Text] [Related]
2. Heat shock (hsp70) and resistance proteins in non-small cell lung carcinomas.
Volm M; Koomägi R; Mattern J; Stammler G
Cancer Lett; 1995 Aug; 95(1-2):195-200. PubMed ID: 7656230
[TBL] [Abstract][Full Text] [Related]
3. Effects of single doses of irradiation on the expression of resistance-related proteins in murine NIH 3T3 and human lung carcinoma cells.
Stammler G; Pommerenke EW; Mattern J; Volm M
Carcinogenesis; 1995 Sep; 16(9):2051-5. PubMed ID: 7554053
[TBL] [Abstract][Full Text] [Related]
4. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.
Masanek U; Stammler G; Volm M
Anticancer Drugs; 1997 Feb; 8(2):189-98. PubMed ID: 9073315
[TBL] [Abstract][Full Text] [Related]
5. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Kim WJ; Kakehi Y; Yoshida O
Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
[TBL] [Abstract][Full Text] [Related]
6. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Volm M; Kästel M; Mattern J; Efferth T
Cancer; 1993 Jun; 71(12):3981-7. PubMed ID: 8099529
[TBL] [Abstract][Full Text] [Related]
7. Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer.
Koomägi R; Stammler G; Manegold C; Mattern J; Volm M
Cancer Lett; 1996 Dec; 110(1-2):129-36. PubMed ID: 9018091
[TBL] [Abstract][Full Text] [Related]
8. Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer.
Oberli-Schrämmli AE; Joncourt F; Stadler M; Altermatt HJ; Buser K; Ris HB; Schmid U; Cerny T
Int J Cancer; 1994 Dec; 59(5):629-36. PubMed ID: 7960235
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of protein kinase C, proto-oncogene products and resistance-related proteins in newly diagnosed childhood acute lymphoblastic leukemia.
Volm M; Zintl F; Edler L; Sauerbrey A
Med Pediatr Oncol; 1997 Feb; 28(2):117-26. PubMed ID: 8986147
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of resistance-related proteins in human lung tumors with poor vascularization.
Koomägi R; Mattern J; Volm M
Carcinogenesis; 1995 Sep; 16(9):2129-33. PubMed ID: 7554065
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
12. Effect of nitric oxide synthase on multiple drug resistance is related to Wnt signaling in non-small cell lung cancer.
Li Y; Ma C; Shi X; Wen Z; Li D; Sun M; Ding H
Oncol Rep; 2014 Oct; 32(4):1703-8. PubMed ID: 25070480
[TBL] [Abstract][Full Text] [Related]
13. Cellular predictive factors for the drug response of lung cancer.
Volm M; Rittgen W
Anticancer Res; 2000; 20(5B):3449-58. PubMed ID: 11131647
[TBL] [Abstract][Full Text] [Related]
14. DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer.
Hansen LT; Lundin C; Helleday T; Poulsen HS; Sørensen CS; Petersen LN; Spang-Thomsen M
Lung Cancer; 2003 May; 40(2):157-64. PubMed ID: 12711116
[TBL] [Abstract][Full Text] [Related]
15. [Expression and clinical significance of resistance proteins in initial acute lymphatic leukemia (ALL) in childhood].
Sauerbrey A; Volm M; Zintl F
Klin Padiatr; 1995; 207(4):230-4. PubMed ID: 7564159
[TBL] [Abstract][Full Text] [Related]
16. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy.
Kawai H; Kiura K; Tabata M; Yoshino T; Takata I; Hiraki A; Chikamori K; Ueoka H; Tanimoto M; Harada M
Lung Cancer; 2002 Mar; 35(3):305-14. PubMed ID: 11844606
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
[TBL] [Abstract][Full Text] [Related]
18. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
[TBL] [Abstract][Full Text] [Related]
19. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression.
Henness S; Davey MW; Harvie RM; Davey RA
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):895-902. PubMed ID: 12377343
[TBL] [Abstract][Full Text] [Related]
20. Translational regulation as a novel mechanism for the development of cellular drug resistance.
Schmitz JC; Liu J; Lin X; Chen TM; Yan W; Tai N; Gollerkeri A; Chu E
Cancer Metastasis Rev; 2001; 20(1-2):33-41. PubMed ID: 11831645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
